Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat

Cephalalgia

Volumn 18, Issue 8, 1998, Pages 532-538

  Tfelt Hansen, P ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Administratin forms; Migraine treatment; Number needed to treat (NNT); Randomized clinical trial; Sumatriptan

Indexed keywords

SUMATRIPTAN;

CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MIGRAINE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE AVERSION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, SUBCUTANEOUS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; SAFETY; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 0031760112     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1998.1808532.x     Document Type: Review

References (56)

1. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993;13:238-44
2. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994;5:295-309
3. Wilkinson M, Pfaffenrath V, Schoenen J, Diener H-C, Steiner T. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-57
4. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994;241:463-9
5. Dahlöf C. Sumatriptan nasal spray: a review of data from multinational clinical trials. Funct Neurol 1996;11:150
6. Rapoport AM. Sumatriptan nasal spray: a review of randomised, double-blind, placebo-controlled clinical trials conducted in the USA. Funct Neurol 1996;11:150
7. Russel MB, Holm-Thomsen OE, Nielsen MR, Cleal A, Pilgrim AJ, Olesen J. A randomized, double-blind, placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 1994;14:291-6
8. Gross MLP, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H, on behalf of the United Kingdom study group. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994;34:559-63
9. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: clinical findings. Neurology 1995;45 Suppl 7:S15-20.6
10. Oral sumatriptan dose-defining study group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991;31:300-5
11. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
12. Henry P, d'Allens H, and the French migraine network Bordeaux-Lyon-Grenoble. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993;33:432-5
13. Cutler N, Mushet GR, Davis R, Clements MS, Whitcher L. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995;45 Suppl 7:S5-9
14. Nappi G, Sicuteri F, Byrne M, Roncolaro M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;41:138-44
15. McQuay HJ, Moore A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20
16. Laupacis A, Sackett DI, Roberts RS. An assessment of clinical useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33
17. McQuay H, Carrol D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J 1995;311:1047-52
18. Dechant KL, Clissod SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43:776-9
19. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47:622-51
20. Blakeborough P, Lloyd DK, Arnold WSG. Speed of response to sumatriptan in migraine and cluster headache. Br J Clin Res 1994;5:123-38. (The same trial as (51), but only the results after 30 min are reported here)
21. 1B/1D receptor agonists. Neurology 1997;48 Suppl 3:S21-4
22. The Finnish sumatriptan group and the cardiovascular clinical research group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:332-8
23. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia 1992;12:308-13
24. Dahlöf C, Edwards C, Toth AL. Sumatriptan injection is superior to placebo in the acute treatment of migraine - with regard to both efficacy and general well-being. Cephalalgia 1992;12:214-20
25. Thomson AN, Arthur GP, Bergin PS, Pollock M, Parkin PJ, Flanagan M, et al. Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial. NZ Med J 1993;106:171-3
26. Banerjee M, Findley LJ. Sumatriptan in the treatment of migraine with aura. Cephalalgia 1992;12:39-44
27. Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995;25:464-9
28. Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363-8
29. Ferrari MD, James MH, Bates D, Pilgrim AJ, Ashford EA, Anderson BA, et al. Oral sumatriptan: effect of a second dose, and treatment of headache recurrence. Cephalalgia 1994;14:330-8
30. Rapoport AM, Visser WH, Cutler NR, Alderton CJ, Paulsgrove LA, Davis RL, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995;45:1505-9
31. Cady RK, Rubino J, Crummett D, Littlejohn TW 3rd. Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med 1994;3:766-72
32. Multinational oral sumatriptan and cafergot comparative study group. A randomized, double-blind comparison of sumatriptan in the acute treatment of migraine. Eur Neurol 1991;31:314-22
33. Oral sumatriptan and aspirin plus metoclopramide comparative study group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-84
34. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4
35. Midelfart E, Winnem M. Sumatriptan in the treatment of migraine in general practice (Norwegian). Tidsskr Nor Laegeforen 1994;114:3430-2
36. Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F and the Oral Sumatriptan Italian Study Group. High efficacy and low frequency of headache recurrence after oral sumatriptan. The oral sumatriptan Italian study group. J Int Med Res 1995;23:96-105
37. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, et al. Subcutaneous sumatriptan during migraine aura. Neurology 1994;44:1587-92
38. The S2BM11 study group. Patients preference between 25, 50 and 100 mg oral doses of sumatriptan. Eur J Neurol 1996;3 Suppl 3:86
39. Ensink F-BM. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol 1991;238:S66-9
40. Mathew NT, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol 1992;49:1271-6
41. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995;310:452-4
42. Gardner MJ, Altman DG, editors. Statistics with confidence. London: Br Med J 1989:55
43. The S2BM09 Study Group. A study to compare the efficiency, safety, and tolerability of oral sumatriptan 25, 50 and 100 mg doses in the acute treatment of migraine. Eur J Neurol 1996;3 Suppl 3:149-50
44. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
45. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991;31:323-31
46. Jensen K, Tfelt-Hansen P, Hansen EW, Kreis EH, Pedersen OS. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia 1995;15:423-9
47. Bousser MG, d'Allens H, Richard A, and the Early-Morning Migraine Sumatriptan Study Group. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled study. J Intern Med 1993;234:211-6
48. Facchinetti F, Bonellie G, Kangasneimi P, Pascual J, Shuaib A, for the Sumatriptan Menstrual Migraine Study Group. The efficacy and safety of sumatriptan in the acute treatment of menstrual migraine. Obstet Gynecol 1995;86:911-6
49. Mushet GR, Cady RK, Baker CC, Clements B, Gutterman DL, Davis R. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX® STATdose system. Clin Therapeut 1996;18:687-99
50. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-13
51. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, Bladin PF, et al. Oral sumatriptan in acute migraine. Lancet 1991;338:782-3
52. Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995;45 Suppl 7:S10-14
53. Tfelt-Hansen P, Henry P, Mulder K, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6
54. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/US Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 1996;53:1132-7
55. Centonze V, Polito MB, Di Bari M, Fabbri L, Cassiano MA, Bassi A, et al. Evaluation of the efficacy of oral sumatriptan in the therapy of acute migraine (Italian). Clin Ter 1995;146:721-8
56. Simmons VE, Blakebourough P. The safety profile of sumatriptan. Rev Contemp Pharmacother 1994;5:319-8